Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BBT-369 by Regeneron Pharmaceuticals for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
BBT-369 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
BBT-369 by Regeneron Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval
BBT-369 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
BBT-369 by Regeneron Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
BBT-369 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...